Medidata Solutions, Inc. (MDSO) Shares Bought by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund lifted its position in shares of Medidata Solutions, Inc. (NASDAQ:MDSO) by 72.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,438 shares of the company’s stock after purchasing an additional 8,611 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Medidata Solutions were worth $1,595,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of MDSO. Fortaleza Asset Management Inc. acquired a new stake in shares of Medidata Solutions during the third quarter worth about $155,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Medidata Solutions by 10.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,186 shares of the company’s stock worth $171,000 after buying an additional 208 shares during the last quarter. Parametrica Management Ltd purchased a new position in shares of Medidata Solutions during the second quarter worth about $216,000. Cubist Systematic Strategies LLC purchased a new position in shares of Medidata Solutions during the second quarter worth about $227,000. Finally, ETF Managers Group LLC purchased a new position in shares of Medidata Solutions during the second quarter worth about $233,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Shares of Medidata Solutions, Inc. (MDSO) opened at $66.95 on Tuesday. Medidata Solutions, Inc. has a twelve month low of $47.77 and a twelve month high of $85.92. The firm has a market capitalization of $3,840.30, a P/E ratio of 79.14, a price-to-earnings-growth ratio of 3.95 and a beta of 1.78. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.29 and a quick ratio of 3.37.

Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings data on Thursday, October 26th. The company reported $0.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. Medidata Solutions had a return on equity of 11.54% and a net margin of 7.84%. The company had revenue of $140.08 million for the quarter, compared to analyst estimates of $141.27 million. During the same quarter in the previous year, the company earned $0.28 EPS. The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. equities research analysts forecast that Medidata Solutions, Inc. will post 0.77 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally posted by Stock Observer and is owned by of Stock Observer. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.thestockobserver.com/2017/11/14/medidata-solutions-inc-mdso-shares-bought-by-oregon-public-employees-retirement-fund.html.

In other news, EVP Michael I. Otner sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $70.88, for a total transaction of $708,800.00. Following the sale, the executive vice president now owns 80,674 shares of the company’s stock, valued at approximately $5,718,173.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert Taylor sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $71.39, for a total value of $356,950.00. Following the sale, the director now directly owns 49,372 shares in the company, valued at approximately $3,524,667.08. The disclosure for this sale can be found here. Insiders sold a total of 215,000 shares of company stock worth $14,817,750 in the last ninety days. 5.80% of the stock is owned by corporate insiders.

MDSO has been the topic of a number of research reports. Zacks Investment Research lowered Medidata Solutions from a “hold” rating to a “sell” rating in a report on Friday, July 21st. Wells Fargo & Company lowered their price target on Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating on the stock in a report on Friday, October 27th. J P Morgan Chase & Co raised their price target on Medidata Solutions to $87.00 and gave the stock an “overweight” rating in a report on Tuesday, July 18th. Citigroup Inc. reissued a “buy” rating and set a $95.00 price target (up previously from $94.00) on shares of Medidata Solutions in a report on Monday, July 24th. Finally, SunTrust Banks, Inc. reissued a “buy” rating and set a $92.00 price target on shares of Medidata Solutions in a report on Friday, October 27th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $83.54.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Want to see what other hedge funds are holding MDSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medidata Solutions, Inc. (NASDAQ:MDSO).

Institutional Ownership by Quarter for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply